United Therapeutics has been closely monitoring the rapidly evolving situation around Coronavirus (COVID-19). We are dedicated to providing ongoing support for patients and healthcare providers, and ensuring an uninterrupted supply of drug product.

CADD-Legacy 1

Proven pump for continuous IV delivery of Remodulin and other medicines

CADD-Legacy® 1—for continuous delivery of IV Remodulin

The CADD-Legacy 1 is a proven pump for continuous IV delivery of Remodulin and other medicines.

Benefits of CADD-Legacy 11

  • Easy-to-read display that provides information for programming adjustments and troubleshooting
  • Reliability and durability can mean less downtime and fewer interruptions of therapy
  • Appropriate for patients who are titrating or on a stable dose of Remodulin
  • Up to 2 days between pump refills2
  • Requires patient to dilute Remodulin with diluent and then fill the pump in a sterile field for each refill3
  • Option to have a 7-day supply of Remodulin shipped to patient’s home

Download the Remodulin Referral Form and specify that your patient receives the CADD-Legacy 1 pump.

Mixing Options

On-demand mix at each cassette change (every 2 days)

Premix a 14-day supply with a simple premixing schedule

On-demand mix every two days, or premix a 14-day supply

Simple premixing schedule

On-demand mix every two days, or premix a 14-day supply

SPmix delivers weekly shipments to eligible patients

Learn more

Before introducing the topic of premixing with a patient:

  • Carefully consider your patient’s dosing schedule, mixing proficiency, and diluent
  • Be sure to contact Specialty Pharmacy Services. SPS can answer any questions they may have about premixing and supply the necessary diluent needed for 14-day premixing. Be sure to inform the SP if you deem a patient appropriate for premixing at home

Remind patients to continue to change the reservoir at least every 2 days.

Be sure to share the following information with your patients

  • 14-day premixing should be done only with high-pH glycine diluent. Remodulin cannot be stored for 14 days when mixed with sterile water for injection or 0.9% sodium chloride injection (only 4 hours at room temperature or 24 hours refrigerated)3
  • Reservoir tubing should be capped before storage
  • Do not use reservoirs that have been stored for more than 14 days
  • Use extension tubing with a filter
    • The CADD-MS® 3 should not be used for premixing

IV=intravenous; SP=Specialty Pharmacy.

Remodulin SPmix Program

The Remodulin SPmix Program delivers up to 7 days of premixed IV Remodulin and all necessary supplies to your patients’ homes each week.

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Specific Populations

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpOct19

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Specific Populations

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpOct19

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).

References: 1. Operator’s Manual: CADD-Legacy 1 Ambulatory Infusion Pump. St. Paul, MN: Sims Deltec, Inc; 2000. 2. Benza RL, Tapson VF, Gomberg-Maitland M, et al. One-year experience with intravenous treprostinil for pulmonary arterial hypertension. J Heart Lung Transplant. 2013;32(9):889-896. 3. Remodulin [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2018.